Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG

Biotech Giants' SG&A Expenses: A Decade of Strategic Spending

__timestampCRISPR Therapeutics AGExelixis, Inc.
Wednesday, January 1, 2014511400050829000
Thursday, January 1, 20151340300057305000
Friday, January 1, 201631056000116145000
Sunday, January 1, 201735845000159362000
Monday, January 1, 201848294000206366000
Tuesday, January 1, 201963488000228244000
Wednesday, January 1, 202088208000293355000
Friday, January 1, 2021102802000401715000
Saturday, January 1, 2022102464000459856000
Sunday, January 1, 202376162000542705000
Monday, January 1, 202472977000492128000
Loading chart...

Unveiling the hidden dimensions of data

Navigating SG&A Expenses: A Tale of Two Biotech Giants

In the ever-evolving biotech industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and CRISPR Therapeutics AG from 2014 to 2023. Over this period, Exelixis, Inc. consistently outpaced CRISPR Therapeutics AG in SG&A spending, reflecting its expansive operational scale. Notably, Exelixis's SG&A expenses surged by over 900% from 2014 to 2023, peaking at approximately $543 million in 2023. In contrast, CRISPR Therapeutics AG exhibited a more moderate increase of around 1,400%, reaching about $76 million in 2023. This disparity underscores Exelixis's aggressive market strategies and larger operational footprint. As the biotech landscape continues to shift, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025